Immunotherapy Drugs Extend Survival for Patients With Advanced Melanomas
A decade-long study finds that a combination of nivolumab and ipilimumab significantly extends survival for patients with advanced melanomas, with median survival now over six years. The study, published in the New England Journal of Medicine, shows no increase in adverse effects over 10 years, suggesting these immunotherapy drugs can transform metastatic melanoma into a manageable, long-term condition.
Reference News
A decade-long study finds that a combination of nivolumab and ipilimumab significantly extends survival for patients with advanced melanomas, with median survival now over six years. The study, published in the New England Journal of Medicine, shows no increase in adverse effects over 10 years, suggesting these immunotherapy drugs can transform metastatic melanoma into a manageable, long-term condition.